Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris

NCT01600222 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT01600222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01600222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Maximal Use Systemic Exposure (MUSE) Study Evaluating the Safety and Efficacy of LEO 90100 Used Once Daily in Subjects With Extensive Psoriasis Vulgaris
Lead sponsor
LEO Pharma
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2012
Completion date
May 31, 2013
Enrollment
37 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris